全文获取类型
收费全文 | 3227523篇 |
免费 | 265111篇 |
国内免费 | 13496篇 |
专业分类
耳鼻咽喉 | 44395篇 |
儿科学 | 96630篇 |
妇产科学 | 80890篇 |
基础医学 | 517908篇 |
口腔科学 | 88621篇 |
临床医学 | 287273篇 |
内科学 | 564295篇 |
皮肤病学 | 86886篇 |
神经病学 | 276097篇 |
特种医学 | 126843篇 |
外国民族医学 | 105篇 |
外科学 | 510801篇 |
综合类 | 96136篇 |
现状与发展 | 23篇 |
一般理论 | 2156篇 |
预防医学 | 264215篇 |
眼科学 | 73707篇 |
药学 | 223682篇 |
24篇 | |
中国医学 | 9529篇 |
肿瘤学 | 155914篇 |
出版年
2021年 | 54602篇 |
2020年 | 34823篇 |
2019年 | 57760篇 |
2018年 | 70254篇 |
2017年 | 53507篇 |
2016年 | 58974篇 |
2015年 | 73450篇 |
2014年 | 107559篇 |
2013年 | 172569篇 |
2012年 | 83162篇 |
2011年 | 81331篇 |
2010年 | 113815篇 |
2009年 | 119189篇 |
2008年 | 69645篇 |
2007年 | 71091篇 |
2006年 | 82733篇 |
2005年 | 78088篇 |
2004年 | 80232篇 |
2003年 | 71429篇 |
2002年 | 61556篇 |
2001年 | 102525篇 |
2000年 | 95464篇 |
1999年 | 95521篇 |
1998年 | 64413篇 |
1997年 | 62412篇 |
1996年 | 60151篇 |
1995年 | 55638篇 |
1994年 | 49625篇 |
1993年 | 46395篇 |
1992年 | 66313篇 |
1991年 | 62637篇 |
1990年 | 59163篇 |
1989年 | 58740篇 |
1988年 | 54178篇 |
1987年 | 52893篇 |
1986年 | 49813篇 |
1985年 | 50254篇 |
1984年 | 45928篇 |
1983年 | 42320篇 |
1982年 | 40524篇 |
1981年 | 38216篇 |
1980年 | 35941篇 |
1979年 | 36892篇 |
1978年 | 33045篇 |
1977年 | 30817篇 |
1976年 | 27616篇 |
1975年 | 26180篇 |
1974年 | 26562篇 |
1973年 | 25228篇 |
1972年 | 23721篇 |
排序方式: 共有10000条查询结果,搜索用时 9 毫秒
981.
982.
983.
C.A. AMEZCUA H.R. MACDONALD† C.A. LUM W. YI‡ L.I. MUDERSPACH† L.D. ROMAN† & J.C. FELIX† 《International journal of gynecological cancer》2006,16(3):1336-1341
In this study, we examine the prevalence of finding isolated tumor cells (ITCs) in negative lymph nodes of endometrial cancer patients using immunohistochemistry. Seventy-six endometrial cancer patients with lymph nodes histologically negative for metastatic disease were examined. Nodal tissue sections were stained with anticytokeratin antibodies AE-1 and CAM 5.2. Nodes with single or groups of cells (two to four cells) < or =0.2 mm and showing cytokeratin reactivity were positive for ITCs. Findings were compared to features of the primary tumor and patient outcome. ITCs were present in 31 of 1712 lymph nodes. Fifteen (19.7%) patients had ITC-positive nodes. ITCs involved only pelvic nodes in nine cases, only para-aortic nodes in five cases, and pelvic and para-aortic in one case. Tumor in adnexa was the only pathologic feature associated with nodal ITCs (P= 0.0485). All 15 patients with nodal ITCs were alive at follow-up. One (6.7%) patient suffered recurrent disease but was alive at last encounter. Disease recurred in 5 (8.8%) of 57 patients without nodal ITCs. Two are alive without disease, two alive with disease, and one died from her cancer. In summary, a significant proportion of endometrial cancer patients have ITCs detected by immunohistochemistry in histologically negative regional lymph nodes. 相似文献
984.
985.
986.
The aim of our study was to determine the incidence, timing, and severity of vaginal stenosis in patients with carcinoma of the cervix who had received pelvic and/or vaginal radiotherapy as part of their treatment. We also sought to determine if there were any predisposing factors for the development of stenosis. A retrospective chart review was undertaken for all the patients diagnosed with carcinoma of the cervix between January 1, 1990, and December 31, 2000 and treated with pelvic and/or vaginal radiation at Westmead Hospital. Since January 1, 1990, data regarding vaginal stenosis has been prospectively recorded on all the patients. Data collected included patient demographics, stage of disease, treatments administered, and incidence, timing, and severity of vaginal stenosis. One hundred and eighty-eight patients were treated. Mean age was 58.6 years. Thirteen percent of patients had stage IB disease, 45% had stage II disease, 39.5% had stage III disease, and 1.5% had stage IV disease. One hundred and seventy-nine patients returned for follow-up, and data regarding vaginal toxicity were available in 98%. Twenty-seven percent had grade 1 toxicity (partial stenosis or shortening but not complete occlusion), and 11% had grade 2 (complete occlusion). Stenosis of any grade was noted at a mean of 9.6 months and median of 7.5 months (range, 26 days-5.6 years) from completion of treatment. The only prognostic factor associated with increased risk of stenosis was age greater than 50 years (odds ratio 2.26). Vaginal stenosis is a common complication of pelvic and vaginal radiotherapy, occurring in 38% of patients. Stenosis occurs most often in the first year after treatment. Patients over the age of 50 are most at risk. 相似文献
987.
Rammurti T Kamble George B Selby Martha Mims Mohamed A Kharfan-Dabaja Howard Ozer James N George 《Biology of blood and marrow transplantation》2006,12(5):506-510
Iron overload presenting as exacerbation of hepatic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation has not been previously described. We report 6 patients with established hepatic GVHD in whom iron overload (median serum ferritin, 7231 mug/dL; median transferrin saturation, 77%) resulting from a lifetime median of 20 units of packed red blood cell transfusions was manifested by worsening of liver function. Liver biopsies performed in 4 patients confirmed severe iron overload and also hepatic GVHD. Analysis for the C282Y and H63D hemochromatosis gene mutation was negative for the homozygous state in all 6 patients. Erythropoietin-assisted phlebotomy resulted in normalization of liver function at a median of 7 months and of serum ferritin at a median of 11 months. Immunosuppressive therapy was successfully tapered in all 4 patients who completed the phlebotomy program, and this supported the impression that iron overload, rather than GVHD, was the principal cause of liver dysfunction. At a median follow-up of 50 months (range, 18-76 months) from the transplantation and 25 months (range, 5-36 months) from ferritin normalization, all 4 patients require maintenance phlebotomy. We conclude that iron overload can mimic GVHD exacerbation, thus resulting in unnecessary continuation or intensification of immunosuppressive therapy for GVHD, and that maintenance phlebotomy is necessary after successful iron-reduction therapy. 相似文献
988.
989.
分子靶向药物bevacizumab是针对血管内皮生长因子(VEGF)的重组人源化单克隆抗体,在多种恶性肿瘤的治疗中显示了临床效果。现就bevacizumab的作用机制及其在乳腺癌治疗中的临床研究进展作一综述。 相似文献
990.